辛伐他汀联合环磷腺苷治疗心衰的疗效及对相关血清因子的影响

摘要

Objective:To explore the clinical therapeutic effect of simvastatin combined cyclic adenosine monophos-phate on coronary heart disease (CHD)with chronic heart failure (CHF)and levels of serum-related factors.Meth-ods:A total of 78 CHD patients with CHF hospitalized in our hospital from Jan 2011 to Jan 2012 were selected. They were randomly and equally divided into simvastatin group and combined treatment group using number table, both groups received routine treatment,simvastatin group received simvastatin in addition, while combined treat-ment group received cyclic adenosine monophosphate based on simvastatin group.Therapeutic effect,changes of cardiac function indexes and serum factor levels were compared between two groups before and after treatment.Re-sults:The total effective rate of combined treatment group (92.31%)was significantly higher than that of simvasta-tin group (71.79%),P<0.05;compared with before treatment and simvastatin after treatment,there were signifi-cant rise in left ventricular ejection fraction [LVEF,(33.54±3.34)%,(43.41±3.23)% vs.(55.21±3.45)%] and transmitral early/late diastolic peak flow velocity [E/A,(0.63±0.11),(0.70±0.15)vs.(1.01±0.21)],and significant reductions in levels of brain natriuretic peptide [BNP,(536.74±21.41)ng/ml,(117.23±11.57)ng/ml vs.(78.20±10.92)ng/ml]and C reactive protein [CRP,(24.00±2.34)mg/L,(17.01±1.09)mg/L vs.(8.28± 0.81)mg/L]in combined treatment group,P<0.05~<0.01.Conclusion:Simvastatin combined cyclic adenosine monophosphate possess significant therapeutic effect on chronic heart failure of coronary heart disease,it can signif-icantly improve cardiac function and serum factor levels in CHD patients with chronic heart failure,and possess good clinical application value.%目的：探讨辛伐他汀联合环磷腺苷治疗冠心病慢性心力衰竭（CHF）的临床疗效及对相关血清因子水平的影响。方法：选择我院2011年1月～2012年1月收治的78例冠心病CHF患者，采用数字表法随机均分为辛伐他汀组和联合用药组，辛伐他汀组在常规对症治疗基础上再给予辛伐他汀治疗，联合用药组再在辛伐他汀组基础上加用环磷腺苷，比较两组临床疗效及治疗前后心功能指标和血清因子水平变化。结果：联合用药组总有效率为92.31％，显著高于辛伐他汀组的71.79％（P＜0.05）；与治疗前及辛伐他汀组治疗后比较，联合用药组治疗后左室射血分数[LVEF，（33.54±3.34）％、（43.41±3.23）％比（55.21±3.45）％]和二尖瓣舒张早期/晚期峰值血流速度[E/A，（0.63±0.11）、（0.70±0.15）比（1.01±0.21）]显著增加，脑钠肽[BNP，（536.74±21.41）ng/ml、（117.23±11.57）ng/ml比（78.20±10.92）ng/ml]和C反应蛋白质[CRP，（24.00±2.34）mg/L、（17.01±1.09）mg/L比（8.28±0.81）mg/L]水平显著降低，P＜0.05～＜0.01。结论：辛伐他汀联合环磷腺苷治疗冠心病慢性心力衰竭疗效显著，可明显改善患者心功能及血清因子水平，具有较好的临床应用价值。